Clinical Trials

Numerous clinical trials spanning Phase 1 through Phase 4 evaluate Salbutamol (Albuterol) Sulfate across respiratory indications—including asthma, pediatric asthma, acute exacerbations, and chronic obstructive pulmonary disease—and exploratory cardiometabolic conditions. Sponsored by various pharmaceutical and institutional entities, such as Teva, AstraZeneca, Johns Hopkins All Children's Hospital, and NIAID, these studies assess pharmacokinetic properties and bronchodilatory efficacy across diverse patient populations. These protocols exhibit recruitment statuses encompassing recruiting, active not recruiting, completed, and withdrawn.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07037511 RECRUITING
Asthma; Healthy; Effect of Drug
University of British Columbia
 2025-10-30
NCT05724745 RECRUITING
Asthma; COPD; BOS
Commissariat A L'energie Atomique
 2023-05-26
NCT03522831 ACTIVE_NOT_RECRUITING
Lung Diseases; Cystic Fibrosis
University of British Columbia
 2018-05-01
NCT06473779 ACTIVE_NOT_RECRUITING
Severe Asthma
AstraZeneca
 2024-09-30 PHASE3
NCT06433921 RECRUITING
Asthma; Mild Asthma
GlaxoSmithKline
 2024-08-14 PHASE1
NCT07350421 NOT_YET_RECRUITING
TTN
Latakia University
 2026-01-01
NCT07591558 NOT_YET_RECRUITING
Atelectases, Postoperative Pulmonary; Diabete Mellitus
King Abdullah University Hospital
 2026-06 EARLY_PHASE1
NCT06276231 UNKNOWN
Renal Colic
Oman Medical Speciality Board
 2024-07-01
NCT07378605 NOT_YET_RECRUITING
Bariatric Surgery
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
 2026-01-01
NCT06815679 NOT_YET_RECRUITING
Acute Respiratory Failure; Pneumonia
Università degli Studi di Ferrara
 2025-03-01 PHASE2; PHASE3
NCT04012138 COMPLETED
Hyperkalemia
Nantes University Hospital
 2019-12-20 PHASE4
NCT05527704 ACTIVE_NOT_RECRUITING
TTN; Respiratory Failure; PPHN
Medical University of Warsaw
 2021-12-31 PHASE3
NCT06036823 COMPLETED
Hyperkalemia; Potassium Imbalance; Electrolyte Imbalance; Electrolyte Disturbance
Oman Medical Speciality Board
 2023-10-01 PHASE4
NCT06027606 COMPLETED
Healthy
University of Alberta
 2023-09-01 PHASE1
NCT06261957 COMPLETED
Asthma
GlaxoSmithKline
 2024-05-31 PHASE3
NCT06426082 UNKNOWN
Cardiometabolic Diseases
Universidad de Almeria
 2024-11-01
NCT06158893 UNKNOWN
Preoperative Inhalation of Budesonide and Salbutamol in Children Undergoing Tonsillectomy
Assiut University
 2024-08 PHASE4
NCT05860244 UNKNOWN
Walking Capacity; Amyotrophic Lateral Sclerosis
Assistance Publique - Hôpitaux de Paris
 2024-09 PHASE2
NCT05914285 ACTIVE_NOT_RECRUITING
One-lung Ventilation; Chronic Obstructive Pulmonary Disease
Yonsei University
 2023-04-25
NCT05667727 COMPLETED
Shortness of Breath; Asthma in Children; Epinephrine Causing Adverse Effects in Therapeutic Use; Salbutamol Adverse Reaction
Oman Medical Speciality Board
 2023-10-15 PHASE4
NCT05653024 TERMINATED
IgE-mediated Abdominal Pain
Philippe Bégin
 2023-07-01 PHASE3
NCT06482294 UNKNOWN
Asthma
Università degli Studi di Ferrara
 2024-06-18 PHASE2
NCT05099107 COMPLETED
Congenital Myopathy; Neuromuscular Diseases; Musculoskeletal Diseases; Nemaline Myopathy; Centronuclear Myopathy; Myosin Storage Myopathy
Vastra Gotaland Region
 2021-10-25
NCT06665711 NOT_YET_RECRUITING
BRONCHIOLITIS
University of Health Sciences Lahore
 2024-12-03
NCT06921291 COMPLETED
TTN
Khyber Teaching Hospital
 2024-08-01 PHASE1
NCT05977699 COMPLETED
Asthma
University of Saskatchewan
 2024-01-12 PHASE4
NCT06433908 COMPLETED
Asthma; Healthy Participants
GlaxoSmithKline
 2024-06-04 PHASE1
NCT06754631 COMPLETED
Asthma in Children
Muhammad Aamir Latif
 2024-04-01
NCT06918418 COMPLETED
Asthma Exacerbation; Children
Children's Hospital and Institute of Child Health, Multan
 2024-01-01 PHASE4
NCT03556683 COMPLETED
Moderate to Severe Asthma
University of North Carolina, Chapel Hill
 2018-10-01
NCT05550402 UNKNOWN
Asthma; Airway Obstruction; Airway Remodeling; Parasympathetic Nervous System Diseases
Hat Yai Medical Education Center
 2024-02-17
NCT06040424 UNKNOWN
COPD
Neutec Ar-Ge San ve Tic A.Ş
 2023-09-28 PHASE3
NCT06319183 UNKNOWN
Effect of Asthma Medication Salbutamol on Obesity
Tongji University
 2024-03 EARLY_PHASE1
NCT06290102 Recruiting
Asthma
Teva Branded Pharmaceutical Products R&D Inc.
 2024-05-02 Phase 1
NCT06223828 Recruiting
Pediatric Asthma|Critical Illness
Johns Hopkins All Children''s Hospital
 2024-04-02 Phase 2|Phase 3
NCT06136091 Recruiting
Asthma
National Institute of Allergy and Infectious Diseases (NIAID)
 2024-04-23 --
NCT05932316 UNKNOWN
Bronchiectasis; Cystic Fibrosis; Primary Ciliary Dyskinesia; Primary Immune Deficiency; Bronchiolitis Obliterans
Rambam Health Care Campus
 2023-05-20
NCT05884970 UNKNOWN
Agents, Anti Asthmatic; Asthma in Children
Canisius-Wilhelmina Hospital
 2023-03-30 PHASE3
NCT06201156 COMPLETED
Childhood Asthma With Acute Exacerbation
Khyber Teaching Hospital
 2023-12-10
NCT05890638 UNKNOWN
COPD
Neutec Ar-Ge San ve Tic A.Ş
 2023-08-25 PHASE3
NCT05987371 COMPLETED
Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 2023-08-23 PHASE2
NCT06201156 Recruiting
Childhood Asthma With Acute Exacerbation
Khyber Teaching Hospital
 2023-12-10 Not Applicable
NCT04276233 COMPLETED
Asthma
GlaxoSmithKline
 2021-06-29 PHASE4
NCT05589441 UNKNOWN
Liver Transplantation
First Affiliated Hospital Xi'an Jiaotong University
 2022-10-28
NCT05087693 COMPLETED
Asthma and/or Exercise Induced Bronchoconstriction; Ozone Air Pollution
University of British Columbia
 2021-11-01 PHASE4
NCT05786950 COMPLETED
Chronic Obstructive Pulmonary Disease
The First Affiliated Hospital of Guangzhou Medical University
 2023-01-01
NCT04402658 WITHDRAWN
Sports Drug Abuse
Norwegian School of Sport Sciences
 2022-08-01
NCT05791565 COMPLETED
Asthma
GlaxoSmithKline
 2023-04-03 PHASE1
NCT04584034 WITHDRAWN
Wheezing
UMC Utrecht
 2021-09 PHASE4
NCT06139029 COMPLETED
Acute Bronchiolitis
Mardan Medical Complex
 2022-11-15 EARLY_PHASE1
NCT05366764 COMPLETED
Asthma
Sanofi
 2022-06-08 PHASE1
NCT03924635 COMPLETED
Airway Inflammation; Asthma
AstraZeneca
 2019-08-01 PHASE4
NCT03842839 UNKNOWN
Airway Remodeling
Guangzhou Institute of Respiratory Disease
 2018-10-01
NCT04929626 COMPLETED
Status Asthmaticus
Ziauddin University
 2022-01-01 PHASE1
NCT03562195 COMPLETED
Asthma
GlaxoSmithKline
 2018-08-29 PHASE3
NCT04446637 WITHDRAWN
Chronic Obstructive Pulmonary Disease
Neutec Ar-Ge San ve Tic A.Ş
 2021-09-03 PHASE3
NCT06657066 COMPLETED
Asthma Patients
King Edward Medical University
 2021-12-06 PHASE2; PHASE3
NCT04565847 COMPLETED
Cough
McMaster University
 2020-11-30 PHASE2
NCT04615611 UNKNOWN
Healthy
University of Copenhagen
 2020-11-07
NCT04558190 COMPLETED
Insulin Resistance
University of Copenhagen
 2020-09-02
NCT03914638 UNKNOWN
Myasthenia Gravis
University of Aarhus
 2019-04-01 PHASE2; PHASE3
NCT03814954 COMPLETED
Respiratory Distress Score
Makassed General Hospital
 2019-01-01
NCT04979923 UNKNOWN
COVID-19 Acute Respiratory Distress Syndrome
Sheikh Zayed Medical College
 2021-07-01 PHASE1
NCT03866512 COMPLETED
Healthy
University of Exeter
 2019-05-10
NCT03902106 UNKNOWN
Healthy
University of Copenhagen
 2019-03-28
NCT04488705 COMPLETED
Healthy
Enterprise Therapeutics Ltd
 2020-08-13 PHASE1
NCT03880903 UNKNOWN
Acute Bronchiolitis
Assiut University
 2020-07-20 PHASE4
NCT03376932 WITHDRAWN
Asthma
GlaxoSmithKline
 2019-01-18 PHASE3
NCT03199976 TERMINATED
Wheezy Bronchitis; Asthmatic Bronchitis; Wheezing; Obstruction Airway
Helsinki University Central Hospital
 2016-04-20 PHASE4
NCT03620422 COMPLETED
Asthma; Cough
McMaster University
 2019-01-11
NCT04750603 COMPLETED
Asthma in Children
Rambam Health Care Campus
 2018-12-01 PHASE4
NCT03449056 UNKNOWN
Chronic Obstructive Pulmonary Disease; High-flow Nasal Cannula
Poitiers University Hospital
 2019-01-11 PHASE3
NCT03707678 WITHDRAWN
Asthma
GlaxoSmithKline
 2019-01-21 PHASE2
NCT03745261 UNKNOWN
Pulmonary Disease, Chronic Obstructive
Henan University of Traditional Chinese Medicine
 2018-06-20 PHASE3
NCT03287310 COMPLETED
Asthma
GlaxoSmithKline
 2017-10-17 PHASE1
NCT03474081 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2018-03-29 PHASE4
NCT02760719 TERMINATED
Bronchiolitis
University Medical Centre Ljubljana
 2015-12 PHASE2
NCT03184987 COMPLETED
Asthma
GlaxoSmithKline
 2017-06-22 PHASE3
NCT03363191 WITHDRAWN
Asthma
GlaxoSmithKline
 2018-03-07 PHASE4
NCT03493503 COMPLETED
Childhood Asthma With Status Asthmaticus
Erasmus Medical Center
 2017-04-05 PHASE4
NCT03478696 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2018-06-25 PHASE4
NCT03816267 COMPLETED
Bronchial Asthma
Suez Canal University
 2018-05-15 PHASE3
NCT03478683 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2018-06-25 PHASE4
NCT02924688 COMPLETED
Asthma
GlaxoSmithKline
 2016-10-13 PHASE3
NCT03436225 UNKNOWN
Bronchiolitis; Respiratory Syncytial Virus
Assiut University
 2019-02 PHASE1
NCT03380429 COMPLETED
Asthma
GlaxoSmithKline
 2018-01-31 PHASE4
NCT03345407 TERMINATED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2017-11-28 PHASE2
NCT03271905 UNKNOWN
COPD; Asthma
Universidade Federal do Rio Grande do Norte
 2017-04-10
NCT02478398 COMPLETED
Rhinitis, Allergic, Seasonal
Merck Sharp & Dohme LLC
 2015-07-20 PHASE3
NCT03296579 UNKNOWN
Asthma Acute; Asthma in Children
University of British Columbia
 2018-06
NCT02782052 WITHDRAWN
Pulmonary Arterial Hypertension
Assistance Publique - Hôpitaux de Paris
 2016-07 PHASE3
NCT03514615 COMPLETED
Scarring
University Hospitals, Leicester
 2018-01-10 PHASE1
NCT03430505 COMPLETED
Asthma
University of Nove de Julho
 2017-06-10
NCT03012061 COMPLETED
Asthma
GlaxoSmithKline
 2017-01-25 PHASE2
NCT02812979 COMPLETED
Chronic Obstructive Pulmonary Disease
University Hospital, Tours
 2016-06
NCT02741271 COMPLETED
Asthma
Organon and Co
 2016-05-11 PHASE3
NCT01721291 COMPLETED
CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ASTHMA; HEALTHY SUBJECTS
Imperial College London
 2012-10-01 PHASE4
NCT03333395 COMPLETED
Mechanically Ventilated Patients
Ain Shams University
 2017-02-01 PHASE4
NCT02576626 COMPLETED
COPD
Wouter H. van Geffen
 2015-12 PHASE4
NCT02925130 COMPLETED
Adrenergic Beta-2 Agonist Effect; Albuterol Effect
University Hospital, Grenoble
 2016-10
NCT02528214 COMPLETED
Asthma
Sanofi
 2015-10-15 PHASE3
NCT03042065 UNKNOWN
Asthma
Centre d'Investigation Clinique et Technologique 805
 2017-03
NCT02720081 COMPLETED
Asthma
Merck Sharp & Dohme LLC
 2016-05-11 PHASE2
NCT02414854 COMPLETED
Asthma
Sanofi
 2015-04-27 PHASE3
NCT02914652 COMPLETED
Ventricular Septal Defect
University of Aarhus
 2016-10-15 PHASE4
NCT02686086 COMPLETED
Chronic Obstructive Pulmonary Disease (COPD)
Beaumont Hospital
 2016-02
NCT02523833 COMPLETED
Hypersensitivity Pneumonitis; Airway Disease Small
University of Sao Paulo General Hospital
 2015-09-01
NCT02863835 COMPLETED
Transplantation, Heart-Lung; Chronic Lung Allograft Dysfunction; Bronchiolitis Obliterans Syndrome
Guy's and St Thomas' NHS Foundation Trust
 2016-04
NCT02654145 COMPLETED
Asthma
GlaxoSmithKline
 2016-03-17 PHASE4
NCT03208894 COMPLETED
Transient Tachypnea of the Newborn
Armed Forces Hospital, Pakistan
 2016-11-01 PHASE3
NCT02729051 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2016-06-29 PHASE3
NCT02127697 WITHDRAWN
Asthma
Novartis Pharmaceuticals
 2015-03 PHASE3
NCT02799784 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2016-07-14 PHASE4
NCT02159196 COMPLETED
Respiratory Failure
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
 2014-07
NCT03059017 COMPLETED
Drug Effect; Pulmonary Disease
British University In Egypt
 2017-02-05 PHASE1
NCT02233985 COMPLETED
Bronchiolitis; Wheezing
Coordinación de Investigación en Salud, Mexico
 2013-08 PHASE4
NCT02818270 COMPLETED
Chronic Obstructive Pulmonary Disease
Chang Gung University
 2016-06
NCT01471340 COMPLETED
Asthma
Organon and Co
 2012-01-09 PHASE4
NCT02371629 COMPLETED
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
 2015-06-24 PHASE4
NCT02731846 WITHDRAWN
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2016-06 PHASE3
NCT02319564 WITHDRAWN
Wheeze
University of Calgary
 2016-04 PHASE4
NCT02592122 UNKNOWN
Lung Disease,Obstructive
snow
 2013-10
NCT03044938 COMPLETED
Asthma; Heart Rate Fast
Universidade Ibirapuera
 2016-08-06 PHASE4
NCT02252302 COMPLETED
Exercise-induced Bronchoconstriction; Air Pollution
University of British Columbia
 2015-05
NCT02299375 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2014-12-09 PHASE2
NCT02483975 COMPLETED
Asthma
GlaxoSmithKline
 2015-10-09 PHASE3
NCT02275052 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2015-01-23 PHASE4
NCT02345161 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2015-01-23 PHASE3
NCT02513160 COMPLETED
Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2015-09-30 PHASE3
NCT02479412 COMPLETED
Asthma; Efficacy; Safety
AstraZeneca
 2015-06-25 PHASE2
NCT02040766 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2013-12 PHASE3
NCT02584738 UNKNOWN
Asthma
Hospital General Naval de Alta Especialidad - Escuela Medico Naval
 2015-09 PHASE4
NCT07436104 COMPLETED
Hypertension (HTN); Diarrhea; Pneumonia; Malaria Fever; COPD; Asthma (Diagnosis); Diarrhea Chronic
MAHAN Trust
 2004-01-01 PHASE4
NCT05006235 COMPLETED
Transient Tachypnea of the Newborn
Ahmed Noaman
 2014-02-01 PHASE1
NCT02502734 COMPLETED
Asthma
GlaxoSmithKline
 2015-09-07 PHASE3
NCT02233803 COMPLETED
Asthma
GlaxoSmithKline
 2014-11-14 PHASE4
NCT02542254 COMPLETED
Chronic Obstructive Pulmonary Disease
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
 2015-10 PHASE2
NCT02160548 COMPLETED
Organophosphate Poisoning
Sylhet M.A.G.Osmani Medical College
 2015-04 PHASE3
NCT02255630 COMPLETED
Ergogenic Athletic Performance
University of British Columbia
 2015-01
NCT02427165 COMPLETED
Asthma
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
 2015-04 PHASE2
NCT02139644 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2014-06 PHASE3
NCT01978418 UNKNOWN
Postnatal Pulmonary Adaptation; Cesarean Section
Sture Andersson
 2013-11 PHASE4
NCT02405598 COMPLETED
Pompe Disease
National Taiwan University Hospital
 2013-10 PHASE4
NCT02175771 COMPLETED
Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2014-07 PHASE3
NCT01958814 COMPLETED
Chronic Respiratory Failure
University Hospital, Tours
 2012-02 PHASE2
NCT02257385 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2014-10-15 PHASE3
NCT01836016 UNKNOWN
Pulmonary Disease, Chronic Obstructive
Henan University of Traditional Chinese Medicine
 2013-05 PHASE3
NCT02296047 COMPLETED
Chronic Obstructive Pulmonary Disease (COPD)
Zhujiang Hospital
 2014-12
NCT02257372 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2014-09-30 PHASE4
NCT02040779 COMPLETED
Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2013-12-26 PHASE3
NCT01903785 COMPLETED
Bronchoconstriction; Inhaled Salbutamol; Cycling Performance
University of British Columbia
 2013-05 PHASE4
NCT02551276 COMPLETED
Muscle Hypertrophy in Healthy Young Men
University of Copenhagen
 2013-11
NCT01854047 COMPLETED
Asthma
Sanofi
 2013-06 PHASE2
NCT01457261 COMPLETED
Idiopathic Pulmonary Fibrosis
Royal Brompton & Harefield NHS Foundation Trust
 2012-04 PHASE1
NCT02031640 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2013-12 PHASE3
NCT01655199 UNKNOWN
Moderate Chronic Obstructive Pulmonary Disease; Severe Chronic Obstructive Pulmonary Disease; Dyspnea
Laval University
 2012-09
NCT01984086 COMPLETED
Asthma
GlaxoSmithKline
 2013-10-21 PHASE1
NCT05749523 WITHDRAWN
Healthy
Vibeke Backer
 2013-11 PHASE4
NCT01957293 COMPLETED
Memory Functions
Prof. Dominique de Quervain, MD
 2013-10 PHASE2
NCT01922271 COMPLETED
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
 2013-08 PHASE4
NCT01470755 COMPLETED
Asthma
Assistance Publique - Hôpitaux de Paris
 2012-01 PHASE2
NCT02069665 COMPLETED
Pneumonia
Liaoning University of Traditional Chinese Medicine
 2011-12
NCT01479621 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2012-01 PHASE2
NCT01576718 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2012-04 PHASE2
NCT01706328 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2012-10-15 PHASE3
NCT01687296 COMPLETED
Asthma
GlaxoSmithKline
 2012-11-12 PHASE3
NCT01714401 COMPLETED
Influence of Nebulized Bronchodilatators on Selected; Electrophysiological Parameters
Medical University of Gdansk
 2012-03
NCT01641692 COMPLETED
Asthma
GlaxoSmithKline
 2012-05 PHASE2
NCT01613326 COMPLETED
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
 2012-06 PHASE3
NCT00608790 UNKNOWN
Tuberculosis
University of Cape Town
 2008-02
NCT01691482 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2012-07-23 PHASE4
NCT01431950 COMPLETED
Asthma
GlaxoSmithKline
 2011-09 PHASE3
NCT01415596 UNKNOWN
Ergogenic Effects of Salbutamol in Healthy Males
Bispebjerg Hospital
 2011-08
NCT01490125 COMPLETED
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
 2011-10 PHASE3
NCT01120691 COMPLETED
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
 2010-04 PHASE3
NCT01313494 COMPLETED
COPD
AstraZeneca
 2011-03 PHASE3
NCT00831376 COMPLETED
Asthma
University of Dundee
 2009-01 PHASE4
NCT02877537 COMPLETED
Asthma
Central Hospital, Nancy, France
 2008-10 PHASE4
NCT01447069 UNKNOWN
Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy; Heart Failure
Rabin Medical Center
 2011-10
NCT01338311 COMPLETED
Asthma
University of Saskatchewan
 2011-03 PHASE4
NCT01425801 COMPLETED
Asthma
AstraZeneca
 2011-08-01 PHASE2
NCT01323621 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2011-03-18 PHASE3
NCT01521572 UNKNOWN
Smoking; Airway Obstruction
Rio de Janeiro State University
 2011-06
NCT00783250 TERMINATED
Chronic Obstructive Pulmonary Disease
IRCCS Azienda Ospedaliero-Universitaria di Bologna
 2008-09 PHASE4
NCT02207452 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2010-08-05 PHASE1
NCT01073527 COMPLETED
Asthma
Wolfson Medical Center
 2009-01
NCT00784758 COMPLETED
Asthma
University of California, Los Angeles
 2009-02
NCT00981851 COMPLETED
Chronic Obstructive Pulmonary Disease; Cardiovascular Disease; Smoking; Bronchodilation
Radboud University Medical Center
 2009-09
NCT01067534 COMPLETED
Bronchodilation
University of Patras
 2010-02
NCT00861926 COMPLETED
Asthma
Chiesi Farmaceutici S.p.A.
 2009-03-20 PHASE3
NCT00440245 COMPLETED
Asthma; COPD
University of Saskatchewan
 2007-02 PHASE4
NCT00523991 COMPLETED
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
 2007-04 PHASE4
NCT00900874 UNKNOWN
Bronchial Asthma
All India Institute of Medical Sciences
 2009-01 PHASE4
NCT01096017 COMPLETED
Asthma
AstraZeneca
 2010-03 PHASE3
NCT00830882 WITHDRAWN
Asthma
University of Dundee
 2009-01 PHASE4
NCT01091337 COMPLETED
Asthma
Otsuka Pharmaceutical, Inc., Philippines
 2006-05 PHASE4
NCT00677729 COMPLETED
Viral Bronchiolitis
Queen's University
 2008-11 PHASE2
NCT00528723 COMPLETED
Bronchial Asthma
Chiesi Farmaceutici S.p.A.
 2007-11 PHASE3
NCT00633919 COMPLETED
Allergy
ALK-Abelló A/S
 2006-07 PHASE2; PHASE3
NCT00673621 COMPLETED
Asthma; Diabetes Mellitus
Mannkind Corporation
 2008-05 PHASE1
NCT00674817 COMPLETED
Pulmonary Disease, Chronic Obstructive
Theravance Biopharma
 2008-04-01 PHASE2
NCT00487773 COMPLETED
Asthma
Medical University of Lodz
 2007-09 PHASE4
NCT00674050 COMPLETED
Diabetes Mellitus; Healthy Subjects
Mannkind Corporation
 2008-05 PHASE1
NCT00696540 UNKNOWN
Bronchiolitis; Respiratory Distress
University Diego Portales
 2008-06 PHASE2
NCT00669617 COMPLETED
Chronic Obstructive Pulmonary Disease
Novartis
 2008-04 PHASE3
NCT00911651 COMPLETED
COPD
University Hospital, Antwerp
 2008-06 PHASE4
NCT00531050 COMPLETED
Chronic Obstructive Pulmonary Disease
Novartis
 2007-08 PHASE2
NCT00990847 COMPLETED
Moderate Acute Asthma
PT Otsuka Indonesia
 2007-06 PHASE3
NCT00180843 TERMINATED
Chronic Obstructive Pulmonary Disease
Imperial College London
 2005-09
NCT00600639 TERMINATED
Acute Respiratory Failure
IRCCS Azienda Ospedaliero-Universitaria di Bologna
 2004-01 PHASE4
NCT00549120 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2007-08-15 PHASE1
NCT00363480 COMPLETED
Asthma
GlaxoSmithKline
 2006-05-17 PHASE4
NCT00384189 COMPLETED
Asthma
AstraZeneca
 2006-09 PHASE3
NCT00315744 COMPLETED
Asthma
GlaxoSmithKline
 2004-11-04 PHASE4
NCT00358488 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2006-04 PHASE2
NCT02177253 COMPLETED
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
 2002-10 PHASE3
NCT00070707 COMPLETED
Rhinitis, Allergic, Seasonal; Asthma
Organon and Co
 2003-04-03 PHASE4
NCT00273962 COMPLETED
Asthma
Boehringer Ingelheim
 2002-05 PHASE4
NCT02182856 COMPLETED
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
 1998-02 PHASE4
NCT02182700 TERMINATED
Asthma
Boehringer Ingelheim
 1998-07 PHASE3
NCT02173678 COMPLETED
Healthy
Boehringer Ingelheim
 1999-10 PHASE1
NCT02235428 TERMINATED
Asthma
Boehringer Ingelheim
 1998-09 PHASE4
NCT02182713 COMPLETED
Asthma
Boehringer Ingelheim
 1998-05 PHASE4
NCT00252863 COMPLETED
Asthma
AstraZeneca
 2004-12 PHASE3
NCT00382889 COMPLETED
Asthma
Chiesi Farmaceutici S.p.A.
 2002-08 PHASE3
NCT00498251 COMPLETED
Lung Injury, Acute; Thoracotomy; Anesthesia; Intensive Care, Surgical; Extravascular Lung Water
University Hospital, Geneva
 2004-09
NCT00497523 COMPLETED
Bronchial Asthma
Chiesi Farmaceutici S.p.A.
 2006-03 PHASE3
NCT00162396 UNKNOWN
Asthma
Hadassah Medical Organization
 1999-08
NCT00117182 COMPLETED
Lung Diseases, Obstructive
Syntara
 2005-07 PHASE2
NCT00114478 UNKNOWN
Bronchiolitis
Kern Medical Center
 2003-11
NCT00272753 COMPLETED
Asthma
AstraZeneca
 2004-04 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-03-13)

Check the Salbutamol (Albuterol) Sulfate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Salbutamol sulfate selectively binds to and activates β2-adrenergic receptors, stimulating adenylate cyclase to increase intracellular cyclic adenosine monophosphate levels. This signaling cascade promotes airway smooth muscle relaxation and inhibits bronchoconstriction, directly counteracting airway hyperresponsiveness in clinical trial conditions such as asthma and chronic obstructive pulmonary disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.